Trial of Boehringer’s cystic fibrosis gene therapy imminent

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

Boehringer’s lentiviral vector-based BI 3720931 candidate will be tested in a phase 1/2 trial, called LENTICLAIR 1, that will be conducted by the company in collaboration with the UK Respiratory Gene Therapy Consortium (GTC) and contract development and manufacturing organisation OXB, with results due in 2027.

Considering the cystic fibrosis transmembrane conductance regulator (CFTR) gene responsible…